Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Omeros is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunologic diseases, specifically targeting the complement system (lectin and alternative pathways) and addictive/compulsive disorders. The company has no commercial products currently in development, having sold its previous commercial product, OMIDRIA, in 2021.
Key Financial Metrics
| Metric | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Net Loss (Continuing Operations) | $(182.6) | $(174.9) |
| Net Loss (Total) | $(156.8) | $(117.8) |
| Net Income from Discontinued Operations | $25.8 | $57.1 |
| Research & Development Expenses | $119.5 | $114.9 |
| Selling, General & Administrative Expenses | $49.7 | $49.7 |
| Cash, Cash Equivalents & Short-Term Investments | $90.1 | $171.8 |
| Net Cash Used in Operating Activities | $(148.8) | $74.7 (Provided) |
| Total Debt (Principal) | $165.0 | $215.9 |
Note: Total Debt includes $97.9 million in 2026 Convertible Senior Notes and $67.1 million in Secured Term Loan principal.
Material Changes vs. Prior Period
- Debt Restructuring: In June 2024, the company entered into a Credit Agreement for a $67.1 million Initial Term Loan. Proceeds were used, along with cash on hand, to repurchase $118.1 million of its 2026 Convertible Senior Notes, reducing the outstanding principal balance by approximately 55%.
- Royalty Monetization: In February 2024, Omeros sold an expanded interest in future OMIDRIA royalties to DRI Healthcare Acquisitions LP for $115.5 million. This transaction eliminated annual caps on royalty payments to DRI for U.S. sales through 2031.
- Operating Cash Flow: Net cash used in operating activities increased significantly to $148.8 million in 2024 compared to cash provided of $74.7 million in 2023. The 2023 positive cash flow was largely driven by the collection of a $200 million milestone payment from Rayner regarding OMIDRIA, which did not recur in 2024.
- Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for one year from the issuance of the financial statements due to recurring losses and upcoming debt maturities.
Guidance, Outlook, and Risks
Product Pipeline & Regulatory Outlook
- Narsoplimab (TA-TMA): A Biologics License Application (BLA) was resubmitted to the FDA in March 2025. The company expects a PDUFA target date in September 2025 if the application is accepted for review. Approval is not guaranteed.
- Zaltenibart (PNH/C3G): Phase 3 clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH) have been initiated. Phase 2 trials for Complement 3 Glomerulopathy (C3G) are ongoing.
- OMS527 (Cocaine Use Disorder): A Phase 1b clinical trial funded by the National Institute on Drug Abuse (NIDA) is expected to begin in 2025.
Financial Outlook & Liquidity
- Cash Runway: As of December 31, 2024, the company held $90.1 million in cash and investments. However, a covenant requires maintaining $25.0 million in unrestricted cash.
- Debt Obligations: The company faces a mandatory prepayment of $20.0 million on its Term Loan in November 2025. The remaining 2026 Convertible Senior Notes mature in February 2026.
- Capital Needs: The company expects to incur additional losses and will need to raise additional capital to fund operations and debt service. It has an "at-the-market" equity offering facility for up to $150.0 million.
Key Risks
- Going Concern: Substantial doubt exists regarding the ability to continue operations without additional financing.
- Regulatory Approval: Failure to obtain FDA approval for narsoplimab or zaltenibart would prevent commercialization and revenue generation.
- Debt Covenants: The Credit Agreement restricts operating flexibility, including limitations on repurchasing stock or incurring additional indebtedness.
- Royalty Dependency: Future liquidity is partially dependent on OMIDRIA royalty sales by Rayner, which are subject to market and regulatory risks.
Investor Verification Checklist
- BLA Acceptance: Verify if the FDA has accepted the resubmitted narsoplimab BLA for review and the confirmed PDUFA date.
- Debt Refinancing: Monitor progress on refinancing the 2026 Convertible Senior Notes maturing in February 2026.
- Cash Burn Rate: Track quarterly cash usage against the $90.1 million balance to assess runway before the November 2025 mandatory loan prepayment.
- OMIDRIA Royalties: Review Rayner's sales reports to assess the likelihood of future milestone payments from DRI (up to $55 million total).
- Equity Dilution: Monitor utilization of the $150 million "at-the-market" equity offering facility and potential dilution from convertible note conversions.